AMAG Pharmaceuticals Inc $ 13.75 0 (0%)
Volume:
0
Avg Vol (1m):
0
Market Cap $:
477.47 Mil
Enterprise Value $:
619.79 Mil
P/E (TTM):
0.00
P/B:
1.86
Financial Strength | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.54 | ||
| Equity-to-Asset | 0.35 | ||
| Debt-to-Equity | 1.22 | ||
| Debt-to-EBITDA | -1.86 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | -1.7 | ||
| Beneish M-Score | -2.85 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -11.6 | ||
| Net Margin % | -75.06 | ||
| ROE % | -74.59 | ||
| ROA % | -28.8 | ||
| ROC (Joel Greenblatt) % | -869.61 | ||
| 3-Year Revenue Growth Rate | -8.2 |
AMAG
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 30.58 | ||
| PB Ratio | 1.86 | ||
| PS Ratio | 1.55 | ||
| EV-to-EBIT | -3.06 | ||
| EV-to-EBITDA | -3.71 | ||
| EV-to-Revenue | 2.04 | ||
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.61 | ||
| Days Inventory | 108.3 | ||
| Days Sales Outstanding | 81.17 | ||
| Days Payable | 35.84 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 0.78 | ||
| Price-to-Median-PS-Value | 0.45 | ||
| Earnings Yield (Greenblatt) % | -32.68 | ||
| Forward Rate of Return (Yacktman) % | -10.78 |